<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
<channel>
                    <title>Urology</title>
            <link>https://medicalxpress.com/urology-news/</link>
            <language>en-us</language> 
            <description>Latest medical news and research in Urology</description>

                            <item>
                    <title>Sperm counts may be falling, but humans are unlikely to run out</title>
                    <description>For years, alarming headlines have warned that sperm counts are plummeting and humanity could be heading toward a fertility crisis. But new research suggests the picture is considerably more complicated.</description>
                    <link>https://medicalxpress.com/news/2026-11-sperm-falling-humans.html</link>
                    <category></category>
                    <pubDate>Tue, 17 Nov 2026 14:40:01 EST</pubDate>
                    <guid isPermaLink="false">news714132385</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2018/2-sperm.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Engineered hydrogel could make testicular reconstruction feel more natural</title>
                    <description>Researchers at UBC&#039;s Okanagan and Vancouver campuses are developing a softer testicular implant that could offer patients a more natural feel following surgical reconstruction.</description>
                    <link>https://medicalxpress.com/news/2026-11-hydrogel-testicular-reconstruction-natural.html</link>
                    <category></category>
                    <pubDate>Fri, 13 Nov 2026 12:20:12 EST</pubDate>
                    <guid isPermaLink="false">news713786781</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/hydrogel.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>What men need to know after a major update to prostate cancer guidelines</title>
                    <description>Middle-aged men should undergo regular screening for prostate cancer, the American Cancer Society said Thursday in a major change to its guidelines.</description>
                    <link>https://medicalxpress.com/news/2026-11-men-major-prostate-cancer-guidelines.html</link>
                    <category></category>
                    <pubDate>Fri, 13 Nov 2026 05:00:04 EST</pubDate>
                    <guid isPermaLink="false">news713765862</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/prostate-cancer-screen.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>American Cancer Society updates prostate cancer screening guideline: Regular PSA testing for average- and high-risk men</title>
                    <description>The American Cancer Society (ACS) today released an updated guideline for prostate cancer screening to help find cancer before it spreads and reduce the risk of dying from the disease. Key changes include a direct recommendation for prostate-specific antigen (PSA)-based screening every two years for average-risk men aged 50–69, with clinicians ensuring patients understand the potential benefits, limitations and harms before starting screening. Also, ACS recommends annual PSA-based screening beginning at 45 years old for Black men and men with a strong family history of prostate cancer.</description>
                    <link>https://medicalxpress.com/news/2026-11-american-cancer-society-prostate-screening.html</link>
                    <category></category>
                    <pubDate>Thu, 12 Nov 2026 13:40:10 EST</pubDate>
                    <guid isPermaLink="false">news713708520</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/updated-acs-prostate-c.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>New guidelines recommend regular prostate cancer screening for all middle-aged men</title>
                    <description>Experts now recommend regular prostate cancer screening for all men ages 50 to 69 and earlier for higher-risk groups, according to new American Cancer Society (ACS) guidelines.</description>
                    <link>https://medicalxpress.com/news/2026-11-guidelines-regular-prostate-cancer-screening.html</link>
                    <category></category>
                    <pubDate>Thu, 12 Nov 2026 13:20:15 EST</pubDate>
                    <guid isPermaLink="false">news713707416</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/man-at-doctors-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>A blood test could help identify men with advanced prostate cancer most likely to benefit from targeted radiotherapy</title>
                    <description>A blood test could help identify men with advanced prostate cancer who are more likely to experience longer disease control following targeted radiotherapy, according to research led by The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London and University College London. The findings are published in the journal JAMA Network Open.</description>
                    <link>https://medicalxpress.com/news/2026-11-blood-men-advanced-prostate-cancer.html</link>
                    <category></category>
                    <pubDate>Thu, 12 Nov 2026 04:00:01 EST</pubDate>
                    <guid isPermaLink="false">news713678292</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/a-blood-test-could-hel.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Molecular brace traps two cancer-driving proteins to suppress prostate cancer growth in preclinical tests</title>
                    <description>Many modern cancer drugs typically target a specific protein or signaling pathway to treat tumors. Now, researchers at the University of Michigan Health Rogel Cancer Center are taking a new approach by throwing a molecular wrench into the machinery driving prostate cancer. In preclinical studies, this new approach demonstrated greater antitumor activity while sparing normal cells.</description>
                    <link>https://medicalxpress.com/news/2026-11-molecular-brace-cancer-proteins-suppress.html</link>
                    <category></category>
                    <pubDate>Wed, 11 Nov 2026 11:00:01 EST</pubDate>
                    <guid isPermaLink="false">news713614021</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/a-new-anti-cancer-stra.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Prostate cancer drug combination adds toxicity without clear benefit for tumors lacking targetable mutations</title>
                    <description>The prospective, multicenter, randomized phase 2 ZZ-FIRST clinical trial, led by the Vall d&#039;Hebron Institute of Oncology&#039;s (VHIO) Prostate Cancer Group, evaluated the androgen receptor pathway inhibitor (ARPI) enzalutamide plus the poly(ADP-ribose) polymerase inhibitor (PARPi) talazoparib versus enzalutamide alone in patients with high-tumor-burden metastatic prostate cancer who had not previously received hormone therapy.</description>
                    <link>https://medicalxpress.com/news/2026-11-prostate-cancer-drug-combination-toxicity.html</link>
                    <category></category>
                    <pubDate>Tue, 10 Nov 2026 17:20:08 EST</pubDate>
                    <guid isPermaLink="false">news713545981</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/prostate-cancer-drug-c.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>New drug combination improves survival in patients with muscle-invasive bladder cancer</title>
                    <description>A new treatment approach could help people with an aggressive form of bladder cancer live longer and reduce the chances of their cancer returning or progressing, particularly those who cannot receive standard chemotherapy, according to findings from a large international clinical trial co-led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center.</description>
                    <link>https://medicalxpress.com/news/2026-11-drug-combination-survival-patients-muscle.html</link>
                    <category></category>
                    <pubDate>Mon, 09 Nov 2026 18:30:01 EST</pubDate>
                    <guid isPermaLink="false">news713457716</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/hand-on-bladder.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Study challenges long-held fears about overactive bladder drugs and dementia</title>
                    <description>New research published in JAMA Network Open finds anticholinergic medications, commonly prescribed for overactive bladder (OAB), may not increase dementia risk after all compared to beta-3 agonists, the newer drug class that has been presumed to be safer for the brain.</description>
                    <link>https://medicalxpress.com/news/2026-11-held-overactive-bladder-drugs-dementia.html</link>
                    <category></category>
                    <pubDate>Mon, 09 Nov 2026 10:20:08 EST</pubDate>
                    <guid isPermaLink="false">news713441204</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2022/dementia-6.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Prostate cancer drug shows promise in new clinical trial</title>
                    <description>In a recent Yale-led clinical trial, a new type of prostate cancer drug showed promising results in reducing tumor activity and pain for patients with metastatic prostate cancer.</description>
                    <link>https://medicalxpress.com/news/2026-11-prostate-cancer-drug-clinical-trial.html</link>
                    <category></category>
                    <pubDate>Wed, 04 Nov 2026 10:40:20 EST</pubDate>
                    <guid isPermaLink="false">news713008659</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/prostate-cancer-drug-s.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Researchers identify critical window for boosting immunotherapy response in prostate cancer</title>
                    <description>Researchers at Roswell Park Comprehensive Cancer Center have shown that hormone-blocking therapies commonly used to treat prostate cancers temporarily activate the body&#039;s immune response before those immune effects begin to fade over time. In a new publication in the Journal for Immunotherapy of Cancer, a team led by Kent Nastiuk, Ph.D., reports this discovery—and points the way to a treatment strategy for taking advantage of this window of opportunity.</description>
                    <link>https://medicalxpress.com/news/2026-10-critical-window-boosting-immunotherapy-response.html</link>
                    <category></category>
                    <pubDate>Thu, 29 Oct 2026 08:20:25 EDT</pubDate>
                    <guid isPermaLink="false">news712480025</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/researchers-identify-c-8.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Combining targeted therapies significantly boosted survival in kidney cancer study</title>
                    <description>Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer. Saby George, M.D., FACP, professor of oncology in the Department of Medicine, is principal investigator of the trial and first author of the study, newly published in The Lancet Oncology.</description>
                    <link>https://medicalxpress.com/news/2026-10-combining-therapies-significantly-boosted-survival.html</link>
                    <category></category>
                    <pubDate>Wed, 28 Oct 2026 14:40:01 EDT</pubDate>
                    <guid isPermaLink="false">news712413506</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/combining-2-vegf-block.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Novel alpha radiopharmaceutical therapy shows promise in early-phase prostate cancer trial</title>
                    <description>A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a trial published in The Journal of Nuclear Medicine&#039;s Late-Breaking Fast Track.</description>
                    <link>https://medicalxpress.com/news/2026-10-alpha-radiopharmaceutical-therapy-early-phase.html</link>
                    <category></category>
                    <pubDate>Tue, 27 Oct 2026 20:00:01 EDT</pubDate>
                    <guid isPermaLink="false">news712314488</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2025/prostate-cancer.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Patients given apalutamide and hormone therapy around surgery may cut their risk of metastasis or death</title>
                    <description>An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and after prostate cancer surgery was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.</description>
                    <link>https://medicalxpress.com/news/2026-10-patients-apalutamide-hormone-therapy-surgery.html</link>
                    <category></category>
                    <pubDate>Mon, 26 Oct 2026 17:00:06 EDT</pubDate>
                    <guid isPermaLink="false">news712248111</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/perioperative-apalutam.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>New treatment approach shows promise in reducing prostate cancer spread</title>
                    <description>Adding darolutamide to standard treatment for aggressive prostate cancer reduced the risk of the disease spreading in an international phase 3 trial.</description>
                    <link>https://medicalxpress.com/news/2026-10-treatment-approach-prostate-cancer.html</link>
                    <category></category>
                    <pubDate>Mon, 26 Oct 2026 15:00:10 EDT</pubDate>
                    <guid isPermaLink="false">news712235464</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/prostate-cancer-2.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Adding abiraterone to ADT and docetaxel improves survival in metastatic prostate cancer</title>
                    <description>Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification. The findings come from almost eight years of follow-up in the academically led phase 3 PEACE-1 trial presented at the ESMO Congress 2026.</description>
                    <link>https://medicalxpress.com/news/2026-10-adding-abiraterone-adt-docetaxel-survival.html</link>
                    <category></category>
                    <pubDate>Mon, 26 Oct 2026 09:40:01 EDT</pubDate>
                    <guid isPermaLink="false">news712223305</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2025/prostate-cancer.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Fewer US men are diagnosed with low-risk prostate cancer, and more of them now choose surveillance over treatment</title>
                    <description>An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis published in CANCER indicates a shift toward surveillance in response to concerns of overdiagnosis and overtreatment that have hindered screening in the recent past.</description>
                    <link>https://medicalxpress.com/news/2026-10-men-prostate-cancer-surveillance-treatment.html</link>
                    <category></category>
                    <pubDate>Mon, 26 Oct 2026 03:10:01 EDT</pubDate>
                    <guid isPermaLink="false">news711893641</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/prostrate-cancer.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Diagnostic test could help doctors refine prostate cancer treatment</title>
                    <description>Prostate cancer is the most common cancer in men—in 2013, it affected more than 1 million men across the world. The cancer does not behave the same way in every patient, and doctors have long faced a difficult balancing act between identifying patients who will benefit from more intensive treatment and those who may do just as well without it. Treating someone more aggressively than necessary is associated with increased side effects and poorer quality of life.</description>
                    <link>https://medicalxpress.com/news/2026-10-diagnostic-doctors-refine-prostate-cancer.html</link>
                    <category></category>
                    <pubDate>Fri, 23 Oct 2026 20:40:01 EDT</pubDate>
                    <guid isPermaLink="false">news711972301</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/genomic-test.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Real-world results confirm benefit of antigen therapy for prostate cancer</title>
                    <description>Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with metastatic castration-resistant prostate cancer (mCRPC) in routine clinical practice, consistent with outcomes from the VISION trial. An analysis of outcomes from a French early-access program, the largest real-world cohort of patients studied to date, confirms the benefit-risk profile of the therapy, while also shedding light on patient selection and use trends. This research was published in The Journal of Nuclear Medicine.</description>
                    <link>https://medicalxpress.com/news/2026-10-real-world-results-benefit-antigen.html</link>
                    <category></category>
                    <pubDate>Fri, 23 Oct 2026 13:20:06 EDT</pubDate>
                    <guid isPermaLink="false">news711977370</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/real-world-results-con.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>New AI platform helps uncover promising cancer drug combinations</title>
                    <description>UCLA investigators have developed a new artificial intelligence-based platform that could help scientists identify promising drug combinations to overcome treatment resistance in cancer.</description>
                    <link>https://medicalxpress.com/news/2026-10-ai-platform-uncover-cancer-drug.html</link>
                    <category></category>
                    <pubDate>Thu, 22 Oct 2026 16:00:20 EDT</pubDate>
                    <guid isPermaLink="false">news711898983</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2024/cancer.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Dehydration, UTIs and cognitive health: Getting enough to drink is complicated for people with brain disorders</title>
                    <description>For older adults with dementia or Parkinson&#039;s disease, staying hydrated can be more complicated than simply drinking more water.</description>
                    <link>https://medicalxpress.com/news/2026-10-dehydration-utis-cognitive-health-complicated.html</link>
                    <category></category>
                    <pubDate>Thu, 22 Oct 2026 10:20:17 EDT</pubDate>
                    <guid isPermaLink="false">news711879199</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/dehydration-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>DNA once dismissed as &#039;noise&#039; reveals new bacterial species in prostate cancer patients</title>
                    <description>University of East Anglia researchers have discovered the genetic blueprints of 18 new bacterial species collected from prostate cancer patients.</description>
                    <link>https://medicalxpress.com/news/2026-10-dna-dismissed-noise-reveals-bacterial.html</link>
                    <category></category>
                    <pubDate>Mon, 19 Oct 2026 19:00:06 EDT</pubDate>
                    <guid isPermaLink="false">news711634023</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2019/5-bacteria.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Targeted radiation shows promise for life-threatening kidney cancer complication</title>
                    <description>When Diane Gentry, a 71-year-old retiree from Watauga, Texas, was diagnosed with stage 4 kidney cancer in 2015, she learned the tumor had grown into her inferior vena cava, the body&#039;s largest vein. This potentially life-threatening complication can require extensive surgery and carries a high risk of cancer recurrence.</description>
                    <link>https://medicalxpress.com/news/2026-10-life-threatening-kidney-cancer-complication.html</link>
                    <category></category>
                    <pubDate>Sun, 18 Oct 2026 11:20:08 EDT</pubDate>
                    <guid isPermaLink="false">news711367149</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/targeted-radiation-sho.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Genomic cancer driver study reveals new clues to why some prostate cancers become aggressive</title>
                    <description>Why do some prostate cancers grow slowly for years, while others progress quickly to life-threatening metastatic disease? An international team of researchers co-led by the Ontario Institute for Cancer Research (OICR) and the University of Copenhagen has uncovered new clues in the genomes of prostate cancers.</description>
                    <link>https://medicalxpress.com/news/2026-10-genomic-cancer-driver-reveals-clues.html</link>
                    <category></category>
                    <pubDate>Fri, 16 Oct 2026 16:20:09 EDT</pubDate>
                    <guid isPermaLink="false">news711376921</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/genomic-cancer-driver.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Smoking may affect fertility in both men and women</title>
                    <description>New research has shed light on how exposure to cigarette smoke could affect reproductive health in both men and women, identifying changes in biological processes involved in ovarian function and sperm production.</description>
                    <link>https://medicalxpress.com/news/2026-10-affect-fertility-men-women.html</link>
                    <category></category>
                    <pubDate>Tue, 13 Oct 2026 19:30:02 EDT</pubDate>
                    <guid isPermaLink="false">news711126302</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/person-smoking.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Same duty cycle, very different outcomes: What tough materials taught us about histotripsy</title>
                    <description>One of the questions that stayed with me throughout my Ph.D. was surprisingly simple: Why are some tissues so much harder to break down with histotripsy than others? Histotripsy is a focused ultrasound technique that uses cavitation bubbles to mechanically break down tissue. Unlike thermal ablation, the goal is not to heat the tissue. Instead, the rapid activity of these bubbles creates mechanical stresses that progressively disrupt tissue structure.</description>
                    <link>https://medicalxpress.com/news/2026-10-duty-outcomes-tough-materials-taught.html</link>
                    <category></category>
                    <pubDate>Mon, 12 Oct 2026 22:00:01 EDT</pubDate>
                    <guid isPermaLink="false">news711029688</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/same-duty-cycle-very-d-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>More men living longer with incurable prostate cancer, report finds</title>
                    <description>Men in England diagnosed with incurable advanced prostate cancer are more likely to survive for at least three years than they were a decade ago, according to an analysis by the London School of Hygiene &amp; Tropical Medicine (LSHTM) and partners.</description>
                    <link>https://medicalxpress.com/news/2026-10-men-longer-incurable-prostate-cancer.html</link>
                    <category></category>
                    <pubDate>Thu, 08 Oct 2026 13:00:16 EDT</pubDate>
                    <guid isPermaLink="false">news710675582</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/man-alone.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Low-risk prostate tumors reveal molecular signs linked to more aggressive cancer</title>
                    <description>A new study revealed molecular features linked to more aggressive prostate cancer in a subset of patients who had been classified as low risk, highlighting biological differences that may not be apparent from clinical measures alone. The results could lead to new therapeutic strategies.</description>
                    <link>https://medicalxpress.com/news/2026-10-prostate-tumors-reveal-molecular-linked.html</link>
                    <category></category>
                    <pubDate>Wed, 07 Oct 2026 16:40:06 EDT</pubDate>
                    <guid isPermaLink="false">news710605686</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/low-risk-prostate-tumo.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Key driver of aggressive prostate cancer identified, suggesting new way to reverse drug resistance</title>
                    <description>Researchers at Fred Hutch Cancer Center have identified a previously overlooked molecular regulator that helps determine whether prostate tumors remain sensitive to treatment or evolve into a more aggressive, drug-resistant form of the disease.</description>
                    <link>https://medicalxpress.com/news/2026-10-key-driver-aggressive-prostate-cancer.html</link>
                    <category></category>
                    <pubDate>Wed, 07 Oct 2026 11:00:02 EDT</pubDate>
                    <guid isPermaLink="false">news710522401</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/key-driver-of-aggressi.jpg" width="90" height="90" />
                                    </item>
                    </channel>
</rss>
